News
Investor's Business Daily on MSN3d
Gilead Dives As Its Biggest Moneymaker Misses. Here's Why It Could Still Be A 'Safe Haven' Stock.Two of Gilead Sciences' most important drugs missed sales expectations late Thursday. Gilead stock fell early Friday.
Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...
In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...
The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...
Combining Trodelvy with Keytruda and pushing it into the frontline setting could “potentially double” the ADC’s market in ...
Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...
Gilead Sciences said a combination of its cancer drug Trodelvy and Merck’s Keytruda delayed the growth of tumors in women ...
Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...
The study enrolled patients with a PD-L1 combined positive score (CPS) of 10 or more, matching Keytruda's label in first-line ...
7d
Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with ...
Gilead Sciences (NasdaqGS:GILD) recently announced positive results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, ...
April 21 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's (MRK.N), opens new tab immunotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback